Scholarlink

<p>We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. Plasma p-tau217 and p-tau181 were measured in participants who were cognitively unimpaired (CU, n = 121), had mild cognitive impairment (n = 102), or dementia (n = 75) from two independent cohorts (Cohort 1: KBASE-V and Cohort 2: Asan) who underwent amyloid PET. In Cohort 1, plasma p-tau217 (area under the curve [AUC] = 0.938, <i>P</i> &lt; 0.001) outperformed p-tau181 (AUC = 0.857, <i>P</i> &lt; 0.001) in predicting amyloid PET positivity (<i>P</i><sub>difference</sub> &lt; 0.001). In Cohort 2, p-tau217 (AUC = 0.893, <i>P</i> &lt; 0.001) and p-tau181 (AUC = 0.856, <i>P</i> &lt; 0.001) showed comparably good discrimination for predicting amyloid PET positivity (<i>P</i> = 0.377). P-tau217 (AUC = 0.852, <i>P</i> &lt; 0.001) and p-tau181 (AUC = 0.828, <i>P</i> &lt; 0.001) demonstrated similarly good discriminations for predicting cognitive stage transition (<i>P</i><sub>difference</sub> = 0.093). Plasma p-tau217 and p-tau181 predicted amyloid PET positivity and cognitive stage transitions well. Plasma p-tau217 might perform better, especially in the early stages.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月6日

查看全文
  • Hyuk Sung Kwon,
  • Mina Hwang,
  • Seong-Ho Koh,
  • Seong Hye Choi,
  • Jae-Hong Lee,
  • Hyung-Ji Kim,
  • So-Hee Park,
  • Hyun-Hee Park,
  • Jee Hyang Jeong,
  • Myung Hoon Han,
  • Ji Young Kim

摘要

We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. Plasma p-tau217 and p-tau181 were measured in participants who were cognitively unimpaired (CU, n = 121), had mild cognitive impairment (n = 102), or dementia (n = 75) from two independent cohorts (Cohort 1: KBASE-V and Cohort 2: Asan) who underwent amyloid PET. In Cohort 1, plasma p-tau217 (area under the curve [AUC] = 0.938, P < 0.001) outperformed p-tau181 (AUC = 0.857, P < 0.001) in predicting amyloid PET positivity (Pdifference < 0.001). In Cohort 2, p-tau217 (AUC = 0.893, P < 0.001) and p-tau181 (AUC = 0.856, P < 0.001) showed comparably good discrimination for predicting amyloid PET positivity (P = 0.377). P-tau217 (AUC = 0.852, P < 0.001) and p-tau181 (AUC = 0.828, P < 0.001) demonstrated similarly good discriminations for predicting cognitive stage transition (Pdifference = 0.093). Plasma p-tau217 and p-tau181 predicted amyloid PET positivity and cognitive stage transitions well. Plasma p-tau217 might perform better, especially in the early stages.